Compare

CJC-1295 (no DAC) vs Ipamorelin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CJC-1295 (no DAC)

265 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 42% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
8
Digestive comfort
-56
Skin appearance
-87
Appetite control
-91
Energy
-1

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-76
Flushing
-157
Headache
-122
GI discomfort
-95
Dizziness
-2

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
2
0.1–0.2 mg
13
0.2–0.4 mg
17
0.4–0.6 mg
13
0.6–1 mg
8
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing29stacking37side effects15cjc-1295 (no dac)23

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 35% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 27 days · Based on 58 repeat reporters

Ipamorelin

530 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 44% · Mixed 46% · Unfavorable overall 10%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
41
Skin appearance
173
Appetite control
167
Energy
143
Mood
73

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
137
Headache
72
GI discomfort
132
Dizziness
139
Fatigue
72

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.1–2 mg

0.1–0.2 mg
6
0.2–0.4 mg
10
0.4–0.6 mg
20
0.6–1 mg
10
1–2 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing14stacking27side effects10ipamorelin13

How repeat users are trending

Among repeat reporters, 54% said they felt similar to their last entry, 30% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 117 repeat reporters

Sources (7)

Published sources linked on the CJC-1295 (no DAC) and Ipamorelin wiki pages.

  1. PubMed

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH-releasing hormone analog

    Teichman SL, Neale A, Lawrence B, et al. J Clin Endocrinol Metab. 2006

    Source
    Wiki study page →
  2. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  3. PubMed

    Advances in the detection of growth hormone releasing hormone synthetic analogs

    Memdouh S, Gavrilović I, Ng K, et al. Drug testing and analysis. 2021

    Source
    Wiki study page →
  4. PubMed

    Ipamorelin, a new growth hormone-releasing peptide

    Johansen PB, Nowak J, Skjaerbaek C, et al. Eur J Endocrinol. 2001

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Ipamorelin growth hormone studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. PubMed

    Ipamorelin, the first selective growth hormone secretagogue

    Raun K, Hansen BS, Johansen NL, et al. European journal of endocrinology. 1998

    Source
    Wiki study page →
  7. PubMed

    The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism

    Lu Z, Ngan MP, Liu JYH, et al. Physiology & behavior. 2024

    Source
    Wiki study page →